Prepayments (CK93) - Nykredit Realkredit A/S
To the Nasdaq Copenhagen
Prepayments (CK93)
Pursuant to s 24 of the Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes prepayment data (CK93) as at 3 March 2023 in the attached file.
Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/.
For further information about data format and contents, please refer to the Nasdaq website.
Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.
Yours sincerely
Nykredit Realkredit A/S
Attachments
- Prepayments - Nykredit Realkredit A_S -06-03-2023
- XML_Ekstraordinære indfrielser_Prepayments - Nykredit Realkredit A_S 06-03-2023
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
CNH Industrial: Periodic Report on a third $50 million tranche of $300 million Buyback Program29.3.2023 22:30:00 CEST | Press release
London, March 29, 2023 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that under a third $50 million tranche (the “Third Tranche”) in the framework of its $300 million common share buyback program, the Company completed transactions in the period March 20, 2023 to March 24, 2023, reported in aggregate, as set forth in the table below. After the purchases announced today and considering those previously executed under the Third Tranche, the total invested amount is approximately €20,017,834.02 ($21,418,144.90) for a total amount of 1,496,705 common shares purchased. DateNumber of common shares purchasedAverage price per share excluding feesConsideration excluding fees Consideration (**) excluding fees(€)(€)($) March 20, 2023 139,705 12.9545 1,809,808.42 1,939,571.69 March 22, 2023 183,000 13.6446 2,496,961.80 2,692,973.30 March 23, 2023 256,000 13.4840 3,451,904.00 3,755,326.36 March 24, 2023 262,000 13.3041 3,485,674.20 3,745,356.93 840,705-11,244,348.4212,133,228.28 As of March
Forløb af Lollands Banks generalforsamling den 29. marts 2023.29.3.2023 22:23:38 CEST | pressemeddelelse
Vedhæftet ovennævnte selskabsmeddelelse. Vedhæftet fil Københavns Fondsbørs forløb generalforsamling 2023
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons29.3.2023 22:19:21 CEST | Press release
Company Announcement COPENHAGEN, Denmark; March 29, 2023 –Genmab A/S (Nasdaq:GMAB) -In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The vesting of the restricted stock units granted to Jan G. J. van de Winkel and Anthony Pagano will be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. About Genmab Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab29.3.2023 22:10:21 CEST | Press release
Company Announcement COPENHAGEN, Denmark; March 29, 2023 –Genmab A/S (Nasdaq:GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant90,054restricted stock units to members of managementand employees of the Company and the Company’s subsidiaries and16,276warrants to the employees of the Company andthe Company’s subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the members of executive management will be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The fair value of each restricted stock unit is equa
US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election.29.3.2023 22:02:33 CEST | Press release
March 29, 2023 Announcement no. 2 US healthcare executive Dr. Ninfa Saunders, DHA,MVA, MSN, FACHEand other Board members to be nominated at general meeting; Chris Lindop not standing for re-election. COPENHAGEN, DENMARK and BOSTON, MA, USA, March 29, 2023, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) announces that Chris Lindop, Chairman of the Board of Directors, has for personal reasons decided not to stand for re-election at the upcoming ordinary general meeting. The Board plans to appoint current Vice Chairman, John McDonough, as the new Chairman following the AGM on April 27, 2023. “I am proud to have helped shepherd BioPorto through this period of significant change and opportunity,” said Mr. Lindop. “I am very confident in the Board, Management, and entire team as they commercialize NGAL tests for Acute Kidney Injury (AKI) in Europe and pursue approval of the first authorized AKI biomarker in the US.” The Board also announces that